Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064882 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01064882: Completed Phase 2 study, sponsored by Allergan.
NCT01064882 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 104 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01064882, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence
Primary Outcome
Change from Baseline at Month 3 in eyelash length, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG bimatoprost ophthalmic solution 0.005%
- DRUG bimatoprost ophthalmic solution 0.015%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT01064882 record still lists
NCT01064882 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 3 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT01064882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01064882 about?
NCT01064882 is a clinical study titled "Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence". This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence
What is the current status of trial NCT01064882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2010-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01064882?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), bimatoprost ophthalmic solution 0.005% (DRUG), bimatoprost ophthalmic solution 0.015% (DRUG).
Who is sponsoring clinical trial NCT01064882?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01064882's enrollment target sits among peer trials
104 660th of 2000 higher than 1,337 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia